To even the most optimistic soul, 2022 was not a vintage year for the world of biopharma and medtech. Public markets continued their downward trajectory and many investors sought safe havens far away from the riskier biotech companies. Little more than a handful of IPOs took place and those that did were small and mostly unremarkable.  

The geopolitical and economic landscape at the start of 2023 are hardly reasons to be turning cartwheels, but there are signs that M&A might be picking up and there are some interesting catalysts pending in the coming months. Is the worst behind us?  

For this eBook, the Evaluate Vantage team braced themselves to investigate the good, the bad and the ugly of the past 12 months.



What will the FDA clampdown on the accelerated approval pathway mean for 2023?
Is anyone even whispering about IPOs anymore?
Where are the glimmers of hope across pharma and medtech?
As big caps bounce back, what lies ahead for the smaller players?